DCCT: Disease-Modifying Antirheumatic Drugs Cycle Combination Therapy Research

Sponsor

Shanxi Medical University (Other)

Overall Status

Unknown status

CT.gov ID

NCT01617590

Collaborator

(none)

500

Enrollment

Location

Arms

Duration (Months)

20.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study was intended to assess the efficacy and safety of different Disease-Modifying Antirheumatic Drugs cycle combination regimen using the American College of Rheumatology (ACR) criteria of 20% improvement in symptoms (ACR20) in managing active adult rheumatoid arthritis.

Condition or Disease	Intervention/Treatment	Phase
Rheumatoid Arthritis	Drug: leflunomide Drug: methotrexate	N/A

Study Design

Study Type:

Interventional

Anticipated Enrollment :

500 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A 48-week, Multi-center, Randomized, Open-lable, Controlled Study to Assess the Response (ACR20) Using Different Disease-Modifying Antirheumatic Drugs Cycle Combination Regimen in Adult Patients With Active Rheumatoid Arthritis

Study Start Date :

May 1, 2012

Anticipated Primary Completion Date :

Dec 1, 2013

Anticipated Study Completion Date :

May 1, 2014

Arms and Interventions

Arm	Intervention/Treatment
Experimental: leflunomide Leflunomide 10-20 mg/d	Drug: leflunomide Leflunomide 10-20 mg, orally, once daily for up to 48 weeks. Twelve weeks after the initial Leflunomide induction, patients were randomized into two groups (LEF+CTX:LEF+MTX=2:1) if the DAS 28 were higher than 2.6, or continuing leflunomide use without dosing change. Then, the disease activity was assessed using DAS 28 every 12 weeks. The regimen should remain unchanged if the DAS 28 reached to less than 2.6, otherwise, a third (24 weeks) or fourth (36 weeks) DMARs should be added. Intravenous CTX was administrated once 200-400mg per 3 weeks.
Active Comparator: methotrexate MTX 7.5-15 mg/week	Drug: methotrexate MTX 7.5-15 mg, orally, once weekly for up to 48 weeks. Twelve weeks after the initial MTX induction, patients were randomized into two groups (MTX+CTX:LEF+MTX=2:1) if the DAS 28 were higher than 2.6, or continuing MTX use without dosing change. Then, the disease activity was assessed using DAS 28 every 12 weeks. The regimen should remain unchanged if the DAS 28 reached to less than 2.6, otherwise, a third (24 weeks) or fourth (36 weeks) DMARs should be added. Intravenous CTX was administrated once

Arm

Intervention/Treatment

Experimental: leflunomide

Leflunomide 10-20 mg/d

Drug: leflunomide

Leflunomide 10-20 mg, orally, once daily for up to 48 weeks. Twelve weeks after the initial Leflunomide induction, patients were randomized into two groups (LEF+CTX:LEF+MTX=2:1) if the DAS 28 were higher than 2.6, or continuing leflunomide use without dosing change. Then, the disease activity was assessed using DAS 28 every 12 weeks. The regimen should remain unchanged if the DAS 28 reached to less than 2.6, otherwise, a third (24 weeks) or fourth (36 weeks) DMARs should be added. Intravenous CTX was administrated once 200-400mg per 3 weeks.

Active Comparator: methotrexate

MTX 7.5-15 mg/week

Drug: methotrexate

MTX 7.5-15 mg, orally, once weekly for up to 48 weeks. Twelve weeks after the initial MTX induction, patients were randomized into two groups (MTX+CTX:LEF+MTX=2:1) if the DAS 28 were higher than 2.6, or continuing MTX use without dosing change. Then, the disease activity was assessed using DAS 28 every 12 weeks. The regimen should remain unchanged if the DAS 28 reached to less than 2.6, otherwise, a third (24 weeks) or fourth (36 weeks) DMARs should be added. Intravenous CTX was administrated once

Outcome Measures

Primary Outcome Measures

ACR20 [48 weeks]
Percentage of subjects who meet the response rate of ACR20 at each post-dose visit

Secondary Outcome Measures

ACR50 [48 weeks]
Percentage of subjects who meet the response rate of ACR 50 at week 48
ACR70 [48week]
Percentage of subjects who meet the response rate of ACR 70 at week 48
EULAR response：good response [48 week]
Percentage of subjects who meet the EULAR response criteria of good response at week 48
EULAR response ：moderate response [48 week]
Percentage of subjects who meet the EULAR response criteria of moderate response at week 48

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

RA patients：

Male and female patients aged 18 - 75 years (inclusive).
Body weight between 50 and 100 kg (inclusive).
Post menopausal or surgically sterile female patients are allowed. Female patients of child-bearing potential may participate if they are already on a stable dose of methotrexate. Additional birth control details to be provided at screening. Male patients must use an effective contraception method during the study and at least for 2 months following the completion/discontinuation of the study.
Diagnosis of RA, classified by American Rheumatism Association 1987 revised criteria.
Active disease evaluation (DAS 28 > 3.2).
Patients who using steroids before enrollment, the dose should not be more than 30mg/d, and remain unchanged for more than 30days.
Without use of other disease activity controlling drugs.
Get the informed consent.

Exclusion Criteria:

Advanced patients with severe joints disability.
Pregnant or breast- feeding female patients.
Patients with severe primary disease or impairment of heart, brain, lung, liver (ALT or AST > 1.5 normal value), kidney (sCr > normal value), endocrine, and hematology system.
Concomitant with other rheumatic disease.
Alcohol taken or drug abusing patients.
Patients with congestive heart failure, QT prolongation syndrome or poorly controlled diabetes mellitus. Patients with a history of QTc prolongation will be excluded.
Patients who have received intra-articular or systemic corticosteroid injections having been required for treatment of acute RA flare (not being part of a regular therapeutic regimen) within 4 weeks prior to randomization.